NCT05823779View on ClinicalTrials.gov

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects

UnknownOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

April 1, 2025

Conditions
HIV DiseaseHerpes Simplex 1Herpes Simplex 2
Interventions
OTHER

Blood draw

We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR

Trial Locations (1)

90036

RECRUITING

Global Research Institute, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Rational Vaccines Inc

INDUSTRY

lead

Global Research Institute

INDUSTRY